Nuvectis Pharma, Inc. (NVCT)
- Previous Close
7.10 - Open
7.09 - Bid 6.86 x 100
- Ask 7.15 x 100
- Day's Range
6.93 - 7.39 - 52 Week Range
6.20 - 18.65 - Volume
8,194 - Avg. Volume
95,374 - Market Cap (intraday)
123.315M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-1.43 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.00
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
www.nuvectis.comRecent News: NVCT
Performance Overview: NVCT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVCT
Valuation Measures
Market Cap
124.91M
Enterprise Value
105.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.14%
Return on Equity (ttm)
-168.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.26M
Diluted EPS (ttm)
-1.43
Balance Sheet and Cash Flow
Total Cash (mrq)
19.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.83M
Research Analysis: NVCT
Company Insights: NVCT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NVCT
Daily – Vickers Top Insider Picks for 10/31/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/30/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/27/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/26/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.